Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens

FEMS Immunology and Medical Microbiology

Volumn 52, Issue 2, 2008, Pages 169-179

  Sloat, Brian R ^a   Shaker, Dalia S ^a   Le, Uyen M ^a   Cui, Zhengrong ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Anthrax toxin; Bacteriolysis; dsRNA; Toxin neutralization

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; COMPLEMENT; DOUBLE STRANDED RNA; GAMMA DEXTRO GLUTAMIC ACID; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; PROTECTIVE ANTIGEN 63; PROTEIN LF; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; BACTERIOLYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MIXTURE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIOLYSIS; CELL LINE; CELL SURVIVAL; COMPLEMENT SYSTEM PROTEINS; FEMALE; MACROPHAGES; MICE; MICE, INBRED BALB C; POLY I-C; POLYGLUTAMIC ACID;

EID: 39049083470     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00347.x     Document Type: Article

References (54)

1. Alexopoulou L, Holt AC, Medzhitov R Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 : 732 738.
2. Asahi-Ozaki Y, Itamura S, Ichinohe T et al 2006) Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8 : 2706 2714.
3. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M Montecucco C (2002) Anthrax toxin: a tripartite lethal combination. FEBS Lett 531 : 384 388.
4. Aulinger BA, Roehrl MH, Mekalanos JJ, Collier RJ Wang JY (2005) Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 73 : 3408 3414.
5. Bever CT, Salazar AM, Neely E, Ferraraccio BE, Rose JW, McFarland HF, Levy HB McFarlin DE (1986) Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology 36 : 494 498.
6. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K McGhee JR (2003) Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170 : 5636 5643.
7. Bradley KA, Mogridge J, Mourez M, Collier RJ Young JA (2001) Identification of the cellular receptor for anthrax toxin. Nature 414 : 225 229.
8. Brossier F, Levy M Mock M (2002) Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70 : 661 664.
9. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL Friedlander AM (2004) Anthrax capsule vaccine protects against experimental infection. Vaccine 23 : 43 47.
10. Cornell CJ, Smith KA, Cornwell GG, Burke GP McIntyre OR (1976) Systemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J Natl Cancer Inst 57 : 1211 1216.
11. Cui Z Mumper RJ (2002) Topical immunization using nanoengineered genetic vaccines. J Control Release 81 : 173 184.
12. Dixon TC, Meselson M, Guillemin J Hanna PC (1999) Anthrax. N Engl J Med 341 : 815 826.
13. Feijo SC, Hayes WW, Watson CE Martin JH (1997) Effects of microfluidizer technology on Bacillus lichenformis spores in ice cream mix. J Dair Sci 80 : 2184 2187.
14. Friedlander AM (1999) Clinical aspects, diagnosis and treatment of anthrax. J Appl Microbiol 87 : 303.
15. Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R Estep J (2004) Genetic immunization against anthrax. Vaccine 22 : 1604 1608.
16. Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D Oken MM (2001) Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 19 : 89 92.
17. Guggenheim MA Baron S (1977) Clinical studies of an interferon inducer, polyriboinosinic-polyribocytidylic acid [poly (I)-poly (C)], in children. J Infect Dis 136 : 50 58.
18. Hepler RW, Kelly R, McNeely TB et al 2006) A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24 : 1501 1514.
19. Herman R Baron S (1971) Immunologic-mediated protection of Trypanosoma congolense-infected mice by polyribonucleotides. J Protozool 18 : 661 666.
20. Hermanson G, Whitlow V, Parker S et al 2004) A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 : 13601 13606.
21. Ichinohe T, Watanabe I, Ito S et al 2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79 : 2910 2919.
22. Inglesby TV, O'Toole T, Henderson DA et al 2002) Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 : 2236 2252.
23. Ivins BE Welkos SL (1988) Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4 : 12 19.
24. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW, Gibbs PH Friedlander A (1998) Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 : 1141 1148.
25. Joyce J, Cook J, Chabot D et al 2006) Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 281 : 4831 4843.
26. 2 and a trans-acting element activate transcription from one of two promoters. J Bacteriol 176 : 586 595.
27. Kozel TR, Murphy WJ, Brandt S, Blazar BR, Lovchik JA, Thorkildson P, Percival A Lyons CR (2004) mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci USA 101 : 5042 5047.
28. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P Tough DF (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 : 1009 1015.
29. Levine AS, Sivulich M, Wiernik PH Levy HB (1979) Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res 39 : 1645 1650.
30. Little SF Knudson GB (1986) Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 : 509 512.
31. Makino S, Uchida I, Terakado N, Sasakawa C Yoshikawa M (1989) Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 171 : 722 730.
32. Mesnage S, Tosi-Couture E, Gounon P, Mock M Fouet A (1998) The capsule and S-layer: two independent and yet compatible macromolecular structures in Bacillus anthracis. J Bacteriol 180 : 52 58.
33. Novak JM, Stein MP, Little SF, Leppla SH Friedlander AM (1992) Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem 267 : 17186 17193.
34. Park JH Baron S (1968) Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science 162 : 811 813.
35. Partidos CD, Hoebeke J, Moreau E, Chaloin O, Tunis M, Belliard G, Briand JP, Desgranges C Muller S (2005) The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol 35 : 1521 1529.
36. Perez-Camero G, Congregado F, Bou JJ Munoz-Guerra S (1999) Biosynthesis and ultrasonic degradation of bacterial poly(gamma-glutamic acid). Biotechnol Bioeng 63 : 110 115.
37. Price BM, Liner AL, Park S, Leppla SH, Mateczun A Galloway DR (2001) Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 : 4509 4515.
38. Puziss M, Manning LC, Lynch JW, Barclaye Abelow I Wright GG (1963) Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl Microbiol 11 : 330 334.
39. Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ Wang JY (2003) A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100 : 10925 10930.
40. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP Levine AS (1976) A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 57 : 599 602.
41. Salazar AM, Levy HB, Ondra S et al 1996) Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38 : 1096 1104.
42. Schneerson R, Kubler-Kielb J, Liu TY, Dai ZD, Leppla SH, Yergey A, Backlund P, Shiloach J, Majadly F Robbins JB (2003) Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 100 : 8945 8950.
43. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P Reis e Sousa C (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 : 887 892.
44. Scobie HM Young JA (2005) Interactions between anthrax toxin receptors and protective antigen. Curr Opin Microbiol 8 : 106 112.
45. Scobie HM, Rainey GJ, Bradley KA Young JA (2003) Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 100 : 5170 5174.
46. Sloat BR Cui Z (2006a) Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine 24 : 6405 6413.
47. Sloat BR Cui Z (2006b) Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res 23 : 1217 1226.
48. Sloat BR Cui Z (2006c) Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 23 : 262 269.
49. Turnbull PC, Broster MG, Carman JA, Manchee RJ Melling J (1986) Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 : 356 363.
50. Wang JY Roehrl MH (2005) Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4 : 4.
51. Wang TT, Fellows PF, Leighton TJ Lucas AH (2004) Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol Med Microbiol 40 : 231 237.
52. Welkos SL (1991) Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb Pathog 10 : 183 198.
53. Welkos SL, Vietri NJ Gibbs PH (1993) Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog 14 : 381 388.
54. Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A Richardson C (2006) An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24 : 3953 3963.